U.S. Veterinary Point of Care Diagnostics Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Sample Type, By Indication, By Testing Category, By End-Use, By Country, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The U.S. veterinary point-of-care diagnostics market size was valued at USD 1.04 billion in 2024 and is estimated to grow at a CAGR of 9.2% from 2025 to 2030. The market's growth is predominantly fueled by a surge in spending on pet-related products and services, an expanding number of pet owners, technological advancements, and a strong demand for point-of-care diagnostics.

The rise in the companion animal population is anticipated to drive demand for veterinary healthcare services and increase overall pet spending. Pet owners in the U.S., according to 2024 statistics published by the American Pet Products Association (APPA), are estimated to be spending more than USD 150 billion on their pets, about a 66% rise from the USD 90.5 billion expenditure in 2018. Furthermore, pet owners in the country are estimated to spend about USD 39 billion on veterinary care services & products in 2024. Diagnostic tests like point-of-care (POC) provide immediate results and clinically relevant information without needing a core diagnostic laboratory. Therefore, they can reduce the cost and time associated with veterinary diagnosis. The lateral flow technology applied in POC veterinary lateral flow devices and dipsticks has been used for decades to diagnose infectious diseases among animals.

Moreover, the high number of veterinary patient visits and developed veterinary healthcare infrastructure are further expected to fuel the market growth. Companies are investing in R&D to develop point-of-care diagnostic equipment. For instance, IDEXX developed SDMA test kits, which use AI to assess kidney functions in cats and dogs. Zoetis has a pipeline of point-of-care diagnostics, which is expected to be launched in the coming years. Heska also launched a range of point-of-care diagnostic products to broaden its portfolio.

Another continuously evolving driver of this diagnostic sector is the emergence of novel technologiesfor advancing POC diagnostics in animals. For instance, researchers from Wyss Research Institute at Harvard College have developed a POC diagnostic technology, directEsense, for application in veterinary health. The technology simplifies the diagnostic process by utilizing an electrically active chemical layer on biosensor surfaces to directly detect disease biomarkers and pathogens and eliminates the need for detection labels; this product enhances electrical conductivity and reduces costs associated with traditional diagnostic methods. This research focuses on detecting unique blood serum proteins in companion animals suffering from musculoskeletal injuries and infections. The parties are now aiming for efficient product development and potential future human and environmental health diagnostics applications.

Furthermore, some other advancements, like artificial intelligence (AI), which enhances the speed and accuracy of diagnoses through real-time analysis of medical data, such as X-rays and blood tests, are expected to act as catalysts for future industry growth. Molecular diagnostics facilitate early disease detection by identifying specific pathogens and genetic markers, facilitating personalized medicine tailored to individual animals.

Market Concentration & Characteristics

The U.S. veterinary point-of-care diagnostics industry is moderately concentrated due to the presence of a few companies with higher shares. Several research institutes and key companies are actively undertaking R&D activities to present innovative diagnostic testing and high efficacy for target consumers. For instance, in October 2024, the Beef Cattle Institute, Butterfly Network, and Kansas State University announced a collaboration to research combating respiratory disease in the Bovine population. The partners are conducting chute-side point-of-care ultrasound tests in cattle to test the efficacy of Butterfly Network's new ultrasound-on-chip technology.

The key companies operating in the U.S. Veterinary POC diagnostics industry are undertaking multiple strategic initiatives, such as acquisitions, to strengthen their product portfolios and offer customers diverse, technologically advanced, and innovative products. For instance, in March 2023, Mars Incorporated announced the acquisition of Heska Corporation. This acquisition would enable Mars Petcare's Science & Diagnostics division to expand its diagnostic offerings and broadly promote point-of-care veterinary diagnostics to the global pet healthcare community.

Several industry players are entering into partnerships and collaborations to grow, innovate, and improve their competitiveness by combining the expertise and efforts of different organizations. For instance, in January 2024, Zoetis Diagnostics and Covetrus announced a strategic collaboration. Through this, both companies aim to combine their veterinary expertise by integrating the latter’s veterinary software, Covetrus Pulse, with Zoetis’ expansive diagnostic products portfolio.

Regulatory bodies such as the U.S. FDA and the United States Pharmacopeia support key companies with approvals, thereby fulfilling industry demand and gaining new clients. Such regulatory support further enhances industry growth.

Product Insights

Based on product, consumables, reagents; & kits segment dominated with a share of 55.0% in 2024. This growth is attributed to an increasing number of diagnostics for zoonotic infection, cancer, and multiple other chronic diseases. To address the rising demand for Point-of-Care (POC) testing, there has been a notable increase in the focus on ensuring a continuous and rising supply of consumables. For instance, in December 2024, Zomedica Corp. launched two novel products: canine NT-poBNP POC test assay for use in canine cardiac complications and Truforma In-clinic Biosensor Testing Platform. 

Additionally, the instruments & devices segment is expected to grow at the fastest rate of 9.43% from 2025 to 2030.This segment's growth is driven by rising veterinary product enhancement, the surge in demand, and the advancement of technologies. The demand for animal-derived food products will drive the need for animal immunodiagnostic tests over the forecast period. For instance, in March 2022, Volition entered into a significant supply and license agreement valued at USD 28.0 million with Heska Corporation. This agreement aimed to commercialize Heska's Nu. Q Vet Cancer Screening for canine cancer diagnostic and monitoring at point-of-care. In addition, in January 2024, Center Point Biotech, LLC announced the successful launch of a novel veterinary diagnostic system, AlphaION, which integrates automation and artificial intelligence to improve the hospital/clinic workflow process.

Animal Type Insights

Based on animal type, the companion animals segment held the largest market share, more than 65% in 2024. This growth is attributed to the high ownership of pets across the U.S. For instance, as per a February 2025 article published by Voronoi, nearly 50% of all households, i.e., almost 59 million households in the country, own a pet dog. Furthermore, it is also estimated  that other companion animals like fish, reptile birds, small animals, rabbits, horses, and rabbits make up nearly 10% of the total U.S. households. This surge in pet ownership further escalates the market growth over the forecast years.

The livestock animals segment is projected to grow with the fastest CAGR of 10.2% from 2025 to 2030. The country has experienced a rise in livestock disease outbreaks in recent years, prompting increasing diagnostic screening and institutional research. For instance, according to AVMA reports from February 2025, over 1000 cattle herds from over 16 states are estimated to suffer from the Avian influenza virus type A (H5N1) outbreak.

Indication Insights

Based on indication insights, the infectious disease segment held the largest share of more than 41.0% in 2024. An increasing number of communicable diseases in livestock animals drives the segment. These contagious diseases include Q fever, brucellosis, tuberculosis, trichinellosis, and more. For instance, according to a September 2024 NIH Journal publication, gastrointestinal (GI) disease prevalence in companion dogs is at 30%. Among these diseases, infectious diseases were the most common, affecting more than 17% of the dogs. The findings indicate a significant prevalence of GI disorders, highlighting the need for further investigation and management strategies in canine health.

The general ailments segment will expand with the fastest CAGR of 9.3% from 2025 to 2030. This growth will likely be driven by increasing awareness of veterinary health among the population. Moreover, a few key companies are focusing on innovative diagnostics for general ailments in livestock, which in turn fuels market growth. For instance, in March 2023, PDX Biotech LLC. Announced the launch of a rapid test to diagnose periodontal disease in dogs.  This includes OraStripdx, a user-friendly test strip that changes color based on the concentration of thiols in the patient's oral fluid. The company won Purina's 2023 Innovation Award in Pet Care following this innovative test.

Sample Type Insights

Based on sample type, the blood/plasma/serum segment accounted for the largest share of about 39% in 2024.  This growth is driven by increasing testing for zoonotic diseases and general ailments for the safety of veterinary health. Moreover, affordability, quick results analysis, and high efficiency will likely boost the growth. According to Kirkwood Animal Hospital in the U.S., blood tests in animal diagnostics are routinely advised as a crucial metric for measuring overall animal health. These tests play a significant role in identifying issues before they manifest visibly, allowing for timely intervention to address them.

The urine segment is anticipated to grow with the fastest CAGR over the forecast period. The growth is fueled by the multiple applications provided by urinalysis. Urinalysis applications include cost-effectiveness, easy accessibility, and provide biochemical data. These tests are generally preferred for detecting kidney dysfunction in animals. The segment is also fueled by continuous product launches like the January 2024 launch of Zoetis' AI urine sediment analysis capabilities in its existing product, Vetscan Imagyst. The novel addition involves employing AI to speed up the urinalysis of veterinary samples. 

Testing Category Insights

Parasitology has emerged as the leading testing category, accounting for approximately 18% in 2024. This growth can be attributed to the increasing preference for animal parasitological testing. Parasitological tests are used to diagnose both internal and external parasites in animals. Internal parasitology tests are commonly performed by examining feces for parasite eggs, with roundworm, whipworm, hookworm, Giardia, and coccidia being the most frequently diagnosed internal parasites, as per the Companion Animal Parasite Council (CAPC).

Recently, Zoetis introduced Vetscan Imagyst, a diagnostic platform that uses image recognition technology, algorithms, and cloud-based artificial intelligence (AI) to offer accurate results in various fields, including blood smear analysis, AI fecal testing, and digital cytology image transfer. The technology aims to enhance the efficiency and accuracy of diagnostic tests performed in veterinary clinics, enabling quicker and more precise diagnoses.

On the other hand, hematology is expected to witness the fastest CAGR from 2025 to 2030, mainly due to the constant product launches and the fact that blood testing is the cornerstone and the most basic diagnostic test in veterinary science to be conducted before advancing to further diagnostics. Leading companies like Zoetis are actively involved in improving and expanding their existing products to increase their capabilities. For instance, in December 2024, Zoetis launched Vetscan OptiCell, a screenless POC hematology analyzer incorporated with AI capabilities.

End-use Insights

In 2024, the veterinary hospitals and clinics segment accounted for the largest share, about 54.0%, owing to the growing number of animal patients visiting these medical facilities for treatment and diagnosis and the increasing demand for animal diagnostic testing to detect infectious diseases in both small and large animals.

Government funding to veterinary hospitals and clinics is also a significant factor driving the market forward. Furthermore, the home care settings segment is expected to grow fastest, with a CAGR of 9.7% over the forecast period. Pet owners and other end consumers benefit significantly from advanced veterinary diagnostics, such as in-house analyzers and point-of-care services, which offer convenience and rapid results.

Key U.S. Veterinary Point of Care Diagnostics Company Insights

The key companies in the U.S. veterinary point-of-care diagnostics industry are primarily involved in launching new products, enhancing existing products, forging partnerships to enhance capabilities, etc. Some of the crucial players include IDEXX, Zoetis, NeuroLogica Corp., Heska Corporation, Phibro Animal Health Corporation, and BioPredic International, among others.

There is intense competition between key companies actively engaged in a high degree of innovation, the impact of regulations, mergers and acquisitions, and regional expansion.

Recent Developments

• In August 2024, U.S.-based company Zomedica Corp. expanded its operations globally by assigning a distribution partner in Costa Rica. The company is now in the U.S., Central America, and other global geographies.

• In October 2023, Zomedica Corp. announced a collaboration with the acquisition of Qorvo Biotechnologies LLC (QBT). Under this acquisition, the company would get full access to the TRUFORMA platform, including the instrument, software, and several important veterinary diagnostic assays developed by QBT.

• In January 2023, SKT Telecom announced a strategic partnership with Vetology Innovations and signed a contract with Vieworks, an X-ray medical imaging device manufacturer. This partnership would integrate SKT's AI technologies and Vetology’s expertise in the veterinary domain. Moreover, the contract with Vieworks would supply X-ray detectors and medical devices to other companies.

• In June 2023, Esaote North America, Inc. announced a new veterinary MyLab ^TM X90VET ultrasound system and intelligent proprietary Augmented Insights ^TM Technology. This new veterinary system is designed to provide veterinary care with high-precision imaging and diagnosis.

•  In July 2022, Merck KGaA's Life Science business received funding support amounting to USD 123.7 million from the U.S. Department of Defense and the U.S. Department of Health and Human Services to produce lateral flow membranes crucial for Point-of-Care (POC) tests for both humans and animals.

• In April 2022, Zoetis launched an AI blood smear diagnostic tool for Vetscan Imagyst. This multi-purpose platform leverages artificial intelligence for image analysis and is used for AI digital cytology and fecal analysis for cats and dogs.

U.S. Veterinary Point Of Care Diagnostics Market Report Scope

U.S. Veterinary Point of Care Diagnostics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the U.S. intravenous infusion pump market based on product, animal type, sample type, indication, testing category, and end-use:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables, Reagents, & Kits

  • Instruments & Devices

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others

  • Livestock Animals

    • Cattle

    • Swine

    • Poultry

• Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood/Plasma/Serum

  • Urine

  • Fecal

  • Others

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Infectious Disease

  • General Ailments

  • Others

• Testing Category Outlook (Revenue, USD Million, 2018 - 2030)

  • Hematology

  • Diagnostic Imaging

  • Bacteriology

  • Virology

  • Cytology

  • Clinical Chemistry

  • Parasitology

  • Serology

  • Others

• End-Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals & Clinics

  • Home Care Settings

  • Others